As a former FDA Associate Commissioner who has spent the last two decades consulting foreign ministries of health and other high-level individuals and businesses on healthcare policy issues, I understand the complexities of biopharmaceutical regulatory standards and practices. I recognize the importance of establishing robust partnerships to help facilitate innovation in the medical field, regardless of geographic location. And nowhere is this more timely or important than when it comes to solving America’s drug shortage problems through supply chain diversification.
Congress is acting. Recently proposed bipartisan legislation to establish an FDA Bureau in the Abraham Accords region is a groundbreaking step to align the Middle East’s biotech corridor and represents a legitimate and collaborative extension of the historic Abraham Accords agreement. It’s good for advancing America’s public health and good for advancing peace in the Middle East.
The Abraham Accords nations (especially Israel and the U.A.E) have become synonymous with innovation, particularly in biotechnology and pharmaceuticals, attracting global investment and pushing the boundaries of medical science. An FDA Bureau won’t offer shortcuts but will provide guidance and opportunities for Abraham Accords drug manufacturers and developers to navigate the FDA’s rigorous review processes. Such advice will enable these companies to better prepare their submissions for the U.S. market, ensuring that their groundbreaking technologies and manufacturing prowess can be reviewed more efficiently -- accelerating the availability of potentially life-saving medical solutions to Americans.
